Eli Lilly and Company completes $3.2 Billion Acquisition of Morphic Holding, Boosting Its IBD Pipeline
Eli Lilly and Company completes $3.2 Billion Acquisition of Morphic Holding, Boosting Its IBD Pipeline
08/28/24, 12:15 AM
Location
indianapoliswalthamIndustry
pharmaceutical
manufacturing
health care
biopharma
therapeutics
biotechnology
Eli Lilly and Company has successfully completed the acquisition of Morphic Holding, a biopharmaceutical company specializing in oral integrin therapies for serious chronic diseases. This strategic acquisition significantly strengthens Lilly’s immunology pipeline, adding Morphic’s promising drug candidate, MORF-057, in development for treating inflammatory bowel disease (IBD).
Company Info
Location
Indianapolis, Indiana, United States
Company info
Lilly is a medicine company turning science into healing to make life better for people around the world. They have been pioneering life-changing discoveries for nearly 150 years, and today their medicines help more than 51 million people across the globe. Lilly is focused on redefining diabetes care, treating obesity, advancing the fight against Alzheimer's disease, providing solutions to immune system disorders, and transforming difficult-to-treat cancers into manageable diseases.
Related People
New Feature: Generate AI-Powered Emails Instantly!
Use one of the following options:
- Click the AI button next to your contact's email to generate a draft automatically.
- Use Copy to Clipboard to paste the email into your favorite email service.
- Click Send via Webmail to use Gmail or another online client.
Important: If nothing happens when you click, you might not have a default email client set up.